Table 2.
The characteristics of the included studies
| Study | Country | Sample size | Intervention | Mean age (years) | |||
|---|---|---|---|---|---|---|---|
| Trial group | Control group | Trial group | Control group | Trial group | Control group | ||
| Vishal 2011 [33] | India | 30 | 29 | Aflapin 100 mg | Placebo 100 mg | 53.2 ± 6.5 | 55.3 ± 8.8 |
| Sengupta 2008 [26] | India | 47 | 23 | 5-Loxin 100 mg or 250 mg | Rice bran (placebo) | 52.79 ± 8.47 | 52.43 ± 9.65 |
| Sengupta 2010 [24] | India | 38 | 19 | Aflapin 100 mg or 5-Loxin 100 mg | Excipients (placebo) 100 mg | 52.4 ± 8.87 | 52.4 ± 7.5 |
| Haroyan 2018 [34] | Armenia | 67 | 68 | Boswellic acid 150 mg + curcuminoids 350 mg | Excipients (placebo) 500 mg | 57.91 ± 9.02 | 56.04 ± 8.55 |
| Karimifar 2017 [35] | Iran | 26 | 26 | Boswellia + Elaeagnus Extraction | Ibuprofen | 52.0 ± 8.74 | 52.96 ± 8.57 |
| Notarnicola 2016 [36] | Italty | 54 | 58 | Boswellic acid 15 mg + Methylsulfonylmethane 10,000 mg | Glucosamine sulfate 3000 mg | 58.7 ± 12.5 | 59.5 ± 13.7 |
| Notarnicola 2011 [37] | Italty | 30 | 30 | Boswellic acid 7.5 mg + Methylsulfonylmethane 5000 mg | Placebo | 63.4 ± 8.2 | 60.2 ± 8.6 |